Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

As organs-on-chips advance, their potential for drug discovery grows

By Brian Buntz | January 8, 2021

Emulate brain chip

Cortical neuron staining in the Emulate Brain-Chip. Image courtesy of Emulate Inc.

Engineered microchips with living human cells have the potential to accelerate drug development and replace animal testing, said Dr. Donald Ingber, the founding director of the Wyss Institute for Biologically Inspired Engineering at Harvard University.

The organ-on-a-chip technology could also enable the industry to rethink its business model, Ingber said in a webinar from the Boston-based startup Emulate. While critics routinely criticize the pharmaceutical industry for price gouging, the blockbuster business model’s demise has threatened many firms’ profitability in the sector. R&D costs are another pressure. “It costs over $3 billion to go from the bench to the clinic at this point,” said Dr. Donald Ingber, the founding director of the Wyss Institute for Biologically Inspired Engineering at Harvard University.

Animal studies are a related challenge for the industry. Not only are they “extremely slow,” and pose “major ethical issues,” they frequently don’t predict clinical responses. “We’re talking 70–90% failure rates based on what came out of animal predictions in various different areas,” Ingber said.

The Wyss Institute helped develop organs-on-chips — engineered microchips with living human cells to mimic organ functions — to address these hurdles. A decade ago, Wyss researchers developed a breathing lung on a chip. “We’re trying to create what I like to think of as living three-dimensional cross sections through a major functional unit that will provide a window on a molecular scale [to] living cells inside human tissues and organ structures,” Ingber said.

Emulate, a Wyss spinoff, is working on commercializing such organs-on-chips and corresponding disease models. For the lung chip, Wyss developed models for pulmonary edema, pulmonary thrombosis and drug toxicity. The latter has enabled researchers to mimic the toxicity of drugs that did not appear in animal trials. Wyss scientists have also used the technology to discover new therapeutic targets. A Phase 2 trial is underway related to the technology.

The respiratory models have grown more complex over time. Wyss researchers are using a lung airway chip for COVID-19 therapeutics discovery.

The researchers have also developed an intestine chip that can support a “complex living microbiome composed of hundreds of different types of bacteria,” Ingber said.

They have also created a bone-marrow chip.

A blood-brain barrier chip can help identify strategies to deliver drugs to the brain selectively. “But the ultimate goal is really to recapitulate human pathophysiology. Because this is where disease modeling is where animal models really fail, and to predict human responses to drugs using clinically relevant dose exposures.”

 


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development
Tagged With: Emulate, organ-on-a-chip, organs-on-chips, Wyss Institute for Biologically Inspired Engineering
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE